Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia.

Thumbnail
Name:
Kumaraswamy et al.pdf
Size:
534.9Kb
Format:
PDF
Description:
free file from PubMed's free ...
Download
Cast your vote
 
Your vote was cast
Thank you for your feedback
Authors
Kumaraswamy, Monika
Lin, Leo
Olson, Joshua
Sun, Ching-Fang
Nonejuie, Poochit
Corriden, Ross
Döhrmann, Simon
Ali, Syed Raza
Amaro, Deirdre
Rohde, M cc
Issue Date
2016-05

Metadata
Show full item record
Abstract
The Gram-negative bacillus Stenotrophomonas maltophilia (SM) is an emerging MDR opportunistic pathogen. Recent studies identify a potentially relevant activity of azithromycin against Gram-negative bacteria overlooked in standard bacteriological testing. We investigated azithromycin activity against SM in testing conditions incorporating mammalian tissue culture medium and host defence factors.
Citation
Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia. 2016, 71 (5):1264-9 J. Antimicrob. Chemother.
Affiliation
Helmholtz-Zentrum für Infectionsforschung GmbH, Inhoffenstr.7, 38124 Braunschweig, Germany.
Journal
The Journal of antimicrobial chemotherapy
URI
http://hdl.handle.net/10033/621278
DOI
10.1093/jac/dkv487
PubMed ID
26832758
PubMed Central ID
PMC4830416
Additional Links
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830416/
Type
Article
Language
en
ISSN
1460-2091
Collections

The following license files are associated with this item:

  • Creative Commons
http://creativecommons.org/licenses/by-nc-sa/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/